Last reviewed · How we verify
NCT06158347: HBOT
Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation Dermatitis in Patients with Localized Breast Cancer
NA trial testing hyperbaric oxygen chamber in Breast Cancer in 30 participants. Completed in 25 September 2024.
6 September 2024
Quick facts
| Lead sponsor | Ilsan Cha hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 6 November 2023 |
| Primary completion | 6 September 2024 |
| Estimated completion | 25 September 2024 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- hyperbaric oxygen chamber
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Radiation Dermatitis — all drugs for Radiation Dermatitis →
Sponsor
Ilsan Cha hospital
Who can join
Adults 19 to 69, female only, with Breast Cancer or Radiation Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed to evaluate reducing the incidence of radiation dermatitis by assigning hyperbaric oxygen therapy to patients with localized breast cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy and safety of hyperbaric oxygen therapy for radiation-induced dermatitis in patients with breast cancer: a randomized pilot study.
Lee JY, Hyun MH, Yang G, Lee S. · · 2025 · cited 1× · PMID 40259026 · DOI 10.1007/s00520-025-09463-0
Verify or expand the search:
- PubMed search for NCT06158347
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of hyperbaric oxygen chamber
Trials testing the same drug.
- NCT01985100 — The Use of Hyperbaric Oxygen to Increase the Blood Supply in the Injured, But Still Alive Tissue, Around an Old Stroke · NA · withdrawn
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Ilsan Cha hospital trials
Trials by the same sponsor.
- NCT07251101 — Hemodynamic Effects of Remimazolam vs Propofol During Robot-assisted Gynecologic Surgery · NA · not yet recruiting
- NCT06920810 — Viscum Album for TNBC on Adjuvant Pembrolizumab · Phase 4 · recruiting
- NCT06840106 — Nasal Steam Therapy for Post-extubation Respiratory Events · NA · recruiting
- NCT06590064 — The Relationship Between Upper and Lower Extremity Blood Pressure in Thyroid Surgery Patients Under General Anesthesia · completed
- NCT06158360 — An Observational Study on Postoperative Symptoms After Thyroidectomy (POS-T) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06158347 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ilsan Cha hospital
- Last refreshed: 20 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06158347.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing